CA
LCTX icon

Clearstead Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Clearstead Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,253
Closed -$1.14K – 3175
2025
Q2 		$1.14K Buy
+1,253
New +$743 ﹤0.01% 2418

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clearstead Advisors's LCTX Position: Q3 2025 in Review

Clearstead Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 1,253 shares — an estimated $1.14K sold.

Clearstead Advisors first reported a position in LCTX in Q2 2025 and held it in 1 quarter. The position peaked at $1.14K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Clearstead Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 1,253 Lineage Cell Therapeutics shares in Q3 2025, an estimated $1.14K.
  • Clearstead Advisors first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 1 quarter.
  • Clearstead Advisors's Lineage Cell Therapeutics position peaked at $1.14K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.